A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review

Zhe Xu, Chong Pang, Jidong Sui and Zhenming Gao

Abstract
Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma is an extremely rare liver malignancy that usually lacks characteristic imaging findings and which is often misdiagnosed. We report a 63-year-old woman diagnosed with primary hepatic extranodal marginal zone B-cell lymphoma, MALT type. The patient underwent needle biopsy and radiofrequency ablation (RFA), and showed no signs of relapse during the 12-month postoperative follow-up. This case stresses the rarity of primary hepatic MALT-type lymphoma and the unique and effective treatment for this patient. Our patient received RFA, which showed good efficacy and which provides a new option for the treatment of hepatic MALT lymphoma. We also present our findings from a systematic review to improve the current understanding of this disease.

Keywords
Primary hepatic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone B-cell lymphoma, radiofrequency ablation, fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography, cancer

Date received: 29 December 2020; accepted: 9 February 2021

Corresponding author:
Zhenming Gao, First Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Dalian Medical University, Zhongshan road-467, Shahekou District, Dalian, 116021 China.
Email: gaozhenmingdy2y@163.com
Background

Primary hepatic lymphoma (PHL) is a rare disease that accounts for only 0.1% of liver malignancies, 0.4% of extranodal lymphomas, and 0.016% of non-Hodgkin’s lymphomas (NHL). Primary hepatic marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma accounts for only 3% of all cases of PHL. The concept of MALT lymphoma was first proposed by Isaacson and Wright in 1983 to describe extranodal malignant lymphoma of marginal zone B-cell origin. MALT lymphoma can involve the gastrointestinal tract, salivary gland, conjunctiva, thyroid, lung, breast, and liver. Primary hepatic MALT lymphomas are extremely rare, and there are only a few reports of the clinical characteristics and the best treatment methods. Increasing early recognition of hepatic MALT lymphomas can avoid unnecessary liver resection or reduce the scope of liver resection if the cancer is responsive to preoperative chemotherapy. Herein, we report a case of primary hepatic MALT lymphoma with a review of the relevant literature to provide detailed understanding of primary hepatic MALT lymphoma.

Case presentation

A 63-year-old woman was admitted to the hospital following an incidental discovery of a focal liver mass on ultrasonography. The patient reported no symptoms other than upper abdominal discomfort, and she had no significant medical history. Her physical examination findings were unremarkable, without splenomegaly or superficial lymph node enlargement. All clinical laboratory parameters, namely blood routine examination, hepatic and renal function, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), were within the reference ranges. No hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection was found, and no abnormal rheumatic and immunity indices were identified. In addition, no Helicobacter pylori (HP) infection or tumor was observed by upper gastrointestinal endoscopy.

Abdominal ultrasonography showed a hypoechoic liver mass in segment VI (S6). Enhanced magnetic resonance imaging (MRI) showed a 1.6-×1.7-cm solitary mass with T1 hypointensity and T2 hyperintensity (Figure 1a). The mass was enhanced in the arterial phase and washed out in the portal phase (Figure 1b, c), and the lesion showed low signal intensity in the hepatocyte-specific phase (Figure 1d). No extrahepatic mass was discovered by MRI. Contrast-enhanced ultrasonography (CEUS) showed that the nodular lesion had mild heterogeneous hyperenhancement in the arterial phase, which was washed out in the portal phase (Figure 1e, f). According to the results of the imaging examinations, the tumor was suspected to be hepatocellular carcinoma (HCC). According to the guidelines for the diagnosis and treatment of primary liver cancer in China (2019 edition), when a tumor measures less than 2 cm, the tumor-free survival rate and overall survival rate after radiofrequency ablation (RFA) are similar to rates following surgical resection, but the incidence of complications and the length of hospital stay are lower than with surgical resection. The patient consented to undergo needle biopsy and RFA.

Histological analysis revealed diffuse and uniform infiltration of typical centrocyte-like lymphoid cells, and lymphoepithelial lesions could be observed in some bile ducts infiltrated with these small-to medium-sized lymphocytes. Immunohistochemical staining was positive for CD20, B-cell lymphoma-2 (BCL-2), and CD21 (irregular expansion of the follicular...
Histological evidence of bile duct injury and ductal proliferation was highlighted by cytokeratin AE1/AE3 immunostaining. Moreover, CD3, CD5, CD10, CD23, CD43, BCL-6, and cyclin D1 activity were negative, and the Ki-67 index was approximately 5% (Figure 2). According to the pathological findings, the patient was diagnosed with primary hepatic extranodal marginal zone B-cell MALT type lymphoma.

The patient’s disease was classified as Ann Arbor stage IE. No additional treatment was performed, and close follow-up was recommended. Postoperative computed tomography (CT) of the abdomen showed effective results of the ablation (Figure 3a). The patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) after discharge, and no signs of hypermetabolic tumors were found. No abnormal indicators were found in blood routine examination and liver biochemistry examination of the patient at the follow-up evaluations, which were performed every 3 months. No abnormal MRI findings were observed 1 year after operation (Figure 3b, c, d), and the patient remains well, and has shown no signs of relapse for 12 months postoperation.

**Discussion**

MALT lymphomas are low-grade B-cell lymphomas, among which HP-related gastric MALT lymphoma is the most common. Currently, there are generally recognized
unified standards for the diagnosis and treatment of gastric MALT lymphoma. However, primary hepatic MALT lymphoma is extremely rare, and its etiology, clinical characteristics, and the best treatment methods remain unclear. Therefore, we summarized our case, with a review of the relevant literature to improve the understanding of the disease and to provide clinical evidence for future diagnosis and treatment.

To the best of our knowledge, 113 cases of primary hepatic MALT lymphoma have been reported in 71 articles to date, of which 80 cases (including our case) had relatively detailed clinical data (Table 1). Among the patients in these 113 cases, 43 patients were men (38%) and 48 were women (42%) (the sex was not indicated in the remaining cases), with an age range of 30 to 89 years and a median age of 63.5 years. Most patients (58.8%) were asymptomatic, and most (72.8%) had a single tumor, with a diameter of 0.7 cm to 20 cm.

MALT lymphoma usually develops in chronic inflammation accompanied by infectious pathogens, such as HP-related chronic gastritis and autoimmune diseases. Nevertheless, the cause of primary hepatic MALT lymphoma is not fully understood. Some scholars believe that continuous inflammatory stimulation may induce development of the disease. In previous case reports, primary hepatic MALT lymphoma was considered to be related to primary biliary cirrhosis (PBC), HCV, HBV, HP infection, non-alcoholic steatohepatitis (NASH), and Epstein–Barr virus. However, a meta-analysis involving approximately 16,300 patients with PBC found no significant correlation between PBC and NHL. In the literature review, we identified 22 cases of HBV (19.3%), 16 cases of HCV (14.0%), 8 cases of PBC (7.0%), 2 cases of autoimmune hepatitis (AIH) (1.8%), and 12 cases of HP infection (10.5%). In our case, the patient had no history of HBV, HCV, autoimmune disease, or HP infection. Owing to the rarity of the disease, the exact role of related risk factors in the occurrence of primary hepatic MALT lymphoma requires further investigation.
Imaging findings in PHL have been reported extensively. However, more than 90% of the PHL cases were diffuse large B-cell lymphomas (DLBCL), and there is no characteristic description of hepatic MALT lymphoma imaging findings. Dong et al.\textsuperscript{11} recommended that the possibility of hepatic MALT lymphoma should not be excluded when liver tumors have no obvious space-occupying effect on CT imaging, and the blood vessels and bile ducts in the liver are running normally. In the literature review, there were 36 comprehensive MRI descriptions. Almost all cases showed T1 low signal intensity and T2 high signal intensity, but there was no regular pattern in the arterial and portal phases. CEUS guidelines suggest that CEUS can help in the differential diagnosis of rare liver tumors.\textsuperscript{48} However, the guidelines do not discuss the imaging findings of primary hepatic MALT lymphoma because of the limited number of cases. According to our review of the relevant literature, five cases of primary hepatic MALT lymphoma were diagnosed and analyzed by CEUS (four cases were described in detail), of which two cases showed uneven enhancement in the arterial phase and uneven regression in the portal phase.\textsuperscript{13} Our case showed the

Figure 3. Postoperative abdominal computed tomography showing effective results of ablation position (a). Enhanced MRI findings 12 months after radiofrequency ablation (RFA) were as follows: no abnormal signal on T2-weighted imaging (b), and no wash-in in either the arterial phase (c) or portal phase (d).
Table 1. Summary of the clinical features of cases of primary hepatic MALT lymphoma (including the present case).

| Characteristic                        | Total cases (n=114) |
|---------------------------------------|---------------------|
| Age (years)                           | 63.5 (30–89) median |
| Sex                                   |                     |
| Male                                  | 43 (38%)            |
| Female                                | 48 (42%)            |
| NA                                    | 23 (20%)            |
| Presenting symptom                    |                     |
| Asymptomatic                          | 67 (58.8%)          |
| Pyrexia                               | 1 (0.9%)            |
| Abdominal pain                        | 7 (6.1%)            |
| Weight loss                           | 2 (1.8%)            |
| Generalized weakness                  | 3 (2.6%)            |
| Preexisting liver disease             |                     |
| HBV                                   | 22 (19.3%)          |
| HCV                                   | 16 (14.0%)          |
| PBC                                   | 8 (7.0%)            |
| AIH                                   | 2 (1.8%)            |
| Tumor number                          |                     |
| Solitary                              | 83 (72.8%)          |
| Multiple                              | 17 (14.9%)          |
| Tumor diameter (cm)                   | 3.5 (0.7–20)        |
| Available MRI findings                | 36 (31.6%)          |
| Available ultrasonography findings    | 29 (25.4%)          |
| Available CEUS findings               | 6 (5.3%)            |
| Available 18F-FDG PET/CT findings     | 18 (15.8%)          |
| Mean SUV max                          | 4.7 (3.5–8.6)       |
| Misdiagnosis                          | 24 (21.1%)          |
| Hepatocellular carcinoma              | 19 (16.7%)          |
| Hepatic hemangioma                    | 2 (1.8%)            |
| Cholangiocellular carcinoma           | 3 (2.6%)            |
| Hepatic metastasis                    | 1 (0.9%)            |
| Pseudolymphoma                        | 1 (0.9%)            |
| Type of treatment                     |                     |
| Chemotherapy                          | 21 (18.4%)          |
| Radiotherapy                          | 2 (1.8%)            |
| Chemotherapy + radiotherapy           | 1 (0.9%)            |
| Resection                             | 25 (21.9%)          |
| Resection + chemotherapy              | 13 (11.4%)          |
| Resection + radiotherapy              | 1 (0.9%)            |
| Resection + rituximab                 | 8 (7.0%)            |
| Resection + antiviral treatment       | 2 (1.8%)            |
| Liver transplantation                 | 6 (5.3%)            |
| Radiofrequency ablation               | 2 (1.8%)            |
| No treatment                          | 8 (7.0%)            |
| Follow-up time (months)               | 26.5 (1–111)        |

(continued)
same characteristics. The other two cases showed uniform wash-in and wash-out in the arterial and portal phases, respectively, suggesting susceptibility to HCC. It is atypical to see uneven enhancement in the arterial phase of HCC. Therefore, when the tumor shows uneven wash-in and wash-out during enhanced imaging, hepatic MALT lymphoma should be included in the differential diagnosis. Shiozawa et al. suggested that the feature of no blood vessels penetrating the tumor may distinguish primary hepatic MALT lymphoma from other malignant lymphomas. Compared with dynamic CT and MRI, CEUS can evaluate intratumoral hemodynamics in real time, which is easier and more accurate for visualizing penetrating blood vessels.

The role of 18F-FDG PET/CT in the detection rate, diagnosis, and follow-up of MALT lymphoma remains controversial. Certain types of MALT lymphoma, such as pulmonary, breast, and head and neck, are 18F-FDG avid in most cases, while others, such as gastric MALT lymphoma, are less avid because of the physiological or inflammatory activity resulting in 18F-FDG uptake that can mask oncological lesions. However, the diagnosis of primary hepatic MALT lymphoma by 18F-FDG PET/CT has not been clearly described. In previous reports, PET-CT was performed in 18 cases, and all hepatic MALT lymphomas showed high metabolism with 18F-FDG.

Although the standardized uptake value (SUV) is the most widely used parameter in MALT lymphoma, this measurement is easily affected by many factors. Albano et al. recommended that other metabolic parameters (such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG)), which include both morphological and metabolic characteristics, may be useful in predicting treatment response and prognosis. The relevant parameters can be further refined to effectively assess the prognosis of hepatic MALT lymphoma. A recent study proposed that the 18-FDG metabolic rate of extragastric MALT lymphoma is significantly related to Ki-67 proliferation. When Ki-67 was >15%, the 18-FDG uptake in the lesions was significantly increased; however, only four cases of related hepatic MALT lymphoma were evaluated in the study. Hence, this result needs further study, but is valuable for postoperative prognostic evaluation and follow-up. Importantly, compared with other aggressive lymphomas such as DLBCL, MALT lymphoma has a relatively low FDG uptake intensity.

| Characteristic                          | Total cases (n=114) |
|----------------------------------------|--------------------|
| Outcome                                |                    |
| Disease-free survival at the last follow-up | 59 (51.8%)        |
| Relapse                                | 9 (7.9%)           |
| Death                                  | 5 (4.4%)           |
| (died of other causes)                 |                    |
| Lost to follow-up                      | 17 (14.9%)         |
| NA                                     | 24 (21.1%)         |

The median (range) for age, tumor diameter, and follow-up time is shown. NA: not available; HBV: hepatitis B virus; HCV: hepatitis C virus; PBC: primary biliary cirrhosis; AIH: autoimmune hepatitis; MRI: magnetic resonance imaging; CEUS: contrast-enhanced ultrasonography; 18F-FDG PET/CT: fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography; SUV: standardized uptake value.
patient, 18F-FDG PET/CT was not performed before surgery; however, postoperative 18F-FDG PET/CT showed no hypermetabolic lesions. This not only indicated no extrahepatic lesions but also proved that the RFA was very successful. Whether 18F-FDG PET/CT can also be used for early diagnosis, staging, and treatment of hepatic MALT lymphoma remains unclear, and large samples are necessary for analysis. However, 18F-FDG PET/CT is helpful in the diagnosis of primary hepatic MALT lymphoma when there are no high-uptake lesions in other parts of the body. 18F-FDG PET/CT may become a new method for staging, follow-up, and prognostic evaluation in the future.

Most MALT lymphoma masses are discovered incidentally and lack extrahepatic manifestations, and are often misdiagnosed. Among the retrieved cases from the literature, almost all cases could not be clearly diagnosed before pathological diagnosis. Some cases were diagnosed as other malignant tumors or even benign tumors before surgery or biopsy. We initially diagnosed our case as HCC before surgery; therefore, the diagnosis of primary hepatic MALT lymphoma requires pathological biopsy for confirmation. Pathological biopsy of primary hepatic MALT lymphoma shows that the marginal zone cells infiltrate the epithelium, which can cause the formation of lymphoepithelial lesions. Lymphoepithelial lesions of the bile duct are typical manifestations of primary hepatic MALT lymphoma, which is consistent with our case. Marginal zone B-cell lymphomas are usually positive for CD20 and CD79a, but not for CD5, CD10, CD23, and CD43, and usually express immunoglobulin M (IgM) and Bcl-2. Ki67, p53, and Bcl-6 expression may help distinguish liver marginal zone B-cell lymphoma from DLBCL. Typical liver marginal zone B-cell lymphomas grow slowly, and if these markers are diffusely expressed, the mass is closer to DLBCL. Therefore, extensive immunohistochemical and molecular studies are essential to distinguish lymphoma from other malignant tumors as well as to judge the immunophenotype of the lymphoma.

The treatment recommendations of the United States National Comprehensive Cancer Network for non-gastric MALT lymphomas are radiotherapy, surgery, chemotherapy, and comprehensive treatment. However, it is not possible to design prospective randomized clinical trials to determine the optimal treatment of this cancer because of its rarity. According to the reported literature, 48.2% of the patients underwent surgical resection or liver transplantation after diagnosis, accompanied by adjuvant chemotherapy, and achieved satisfactory postoperative effect. Most patients were cured; however, there were two cases of tumor recurrence during long-term follow-up after surgical resection, suggesting the importance of regular follow-up after treatment. Obiorah et al. reported a case of primary hepatic MALT lymphoma that developed pulmonary MALT lymphoma 1 year after surgical resection and parotid MALT lymphoma after 7 years. Chen et al. reported a patient with primary hepatic MALT lymphoma who developed pulmonary MALT lymphoma 8 years after surgery. Although the disease usually progresses slowly, it may relapse after many years and involve other common external nodes. Therefore, clinicians should be alert to the possibility of distant metastasis, and regular follow-up is recommended even after 5 years postoperatively.

To the best of our knowledge, only one Japanese patient with primary hepatic MALT lymphoma has received RFA treatment. In our case, RFA was performed after confirming a malignant liver tumor. Postoperative imaging results indicated good efficacy with surgery. The patient was regularly followed-up for 1 year after surgery, and showed no signs of recurrence.
Our case indicates that RFA is safe and effective in the treatment of primary hepatic MALT lymphoma in the short-term, while avoiding unnecessary liver resection. However, long-term follow-up and more relevant cases are needed to observe the effect of RFA on long-term survival. As seen in our case, when the tumor is confirmed by pathological biopsy, non-resection therapies, such as RFA, can be selected. Our case indicates a new option for the treatment of hepatic MALT lymphoma.

Conclusions

According to our case and the previous literature, primary hepatic MALT lymphoma is usually identified incidentally, and the disease has no characteristic imaging manifestations. Hence, preoperative diagnosis remains a great challenge. Although there is no standard management model for this rare disease, patients who undergo surgery, chemotherapy, or radiotherapy experience good efficacy and prognosis. Our case received RFA for primary hepatic MALT lymphoma, which showed good efficacy. The effect of RFA on long-term survival requires further follow-up observation, and greater numbers of case reports and multi-center studies are needed to provide detailed clinical information to improve the current understanding of the disease.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Ethics statement

The study protocol was approved by the Ethics Committee of The Second Hospital of Dalian Medical University (approval no: 2020. 050). The patient provided written informed consent.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Zhenming Gao https://orcid.org/0000-0003-0647-1121

References

1. Jaffe ES. Malignant lymphomas: pathology of hepatic involvement. Semin Liver Dis 1987; 7: 257–268.
2. Noronha V, Shafi NQ, Obando JA, et al. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol 2005; 53: 199–207.
3. Lei KI. Primary non-Hodgkin’s lymphoma of the liver. Leuk Lymphoma 1998; 29: 293–299.
4. Isaacson P and Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410–1416.
5. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495.
6. Masood A, Kairouz S, Hudhud KH, et al. Primary non-Hodgkin lymphoma of liver. Curr Oncol 2009; 16: 74–77.
7. Bohlok A, De Grez T, Bouazza F, et al. Primary hepatic lymphoma mimicking a hepatocellular carcinoma in a cirrhotic patient: case report and systematic review of the literature. Case Rep Surg 2018; 2018: 9183717.
8. Chatelain D, Maes C, Yzet T, et al. [Primary hepatic lymphoma of MALT-type: a tumor that can simulate a liver metastasis]. Ann Chir 2006; 131: 121–124.
9. Chen YY, Chen YF and Chen CH. A long-term follow-up of primary hepatic mucosa-associated lymphoid tissue lymphoma. Dig Liver Dis 2020; 52: 1365–1366.
10. Choi S, Kim JH, Kim K, et al. Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. J Pathol Transl Med 2020; 54: 340–345.
11. Dong A, Xiao Z, Yang J, et al. CT, MRI, and 18F-FDG PET/CT findings in untreated pulmonary and hepatic B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) over a five-year period: a case report. Medicine (Baltimore) 2016; 95: e3197.
12. Dong S, Chen L, Chen Y, et al. Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: a case report and literature review. Medicine (Baltimore) 2017; 96: e6305.
13. Foschi FG, Dall’Aglio AC, Marano G, et al. Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med 2010; 29: 1353–1356.
14. Francica G and Lapiccirella G. Focal liver lesions: one more example of discordance between contrast-enhanced sonography and CT pattern of enhancement. AJR Am J Roentgenol 2008; 190: W222.
15. Gherlan GS, Stoia R, Enyedi M, et al. Primary hepatic marginal zone lymphoma in a patient with chronic hepatitis C. Maedica (Buchar) 2016; 11: 250–254.
16. Golli L, Taïeb J, Boleslawski E, et al. [Mucosa-associated lymphoid tissue hepatic lymphoma with low-grade malignancy associated with primary biliary cirrhosis]. Gastroenterol Clin Biol 2003; 27: 127–129.
17. Hamada M, Tanaka Y, Kobayashi Y, et al. [A case of MALT lymphoma of the liver treated by RFA and Rituximab]. Nihon Shokakibyo Gakkai Zasshi 2006; 103: 655–660.
18. Igarashi T, Yokoyama Y, Ikeda T, et al. [Primary biliary cholangitis complicated by primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]. Rinsho Ketsueki 2019; 60: 1532–1537.
19. Khurana A, Mukherjee U and Patil N. An unusual case of hepatic lymphoma with multiple epithelial malignancies. Indian J Pathol Microbiol 2018; 61: 585–586.
20. Kiesewetter B, Müllauer L, Streubel B, et al. Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects. Ann Hematol 2012; 91: 1817–1818.
21. Liu J, Guo RR, Fang JC, et al. Primary hepatic mucosa-associated lymphoid tissue lymphoma with hepatocellular carcinoma: a case report and literature review. J Dig Dis 2020; 21: 526–528.
22. Lu Q, Zhang H, Wang WP, et al. Primary non-Hodgkin’s lymphoma of the liver: sonographic and CT findings. Hepatobiliary Pancreat Dis Int 2015; 14: 75–81.
23. Obiorah IE, Johnson L and Ozdemirli M. Primary mucosa-associated lymphoid tissue lymphoma of the liver: a report of two cases and review of the literature. World J Hepatol 2017; 9: 155–160.
24. Raderer M, Traub T, Formanek M, et al. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer 2001; 85: 1462–1466.
25. Raderer M, Streubel B, Woeheirr S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005; 11: 3349–3352.
26. Takata N, Terasaki S, Iwata A, et al. [Hepatic mucosa-associated lymphoid tissue lymphoma in a patient with chronic hepatitis B]. Nihon Shokakibyo Gakkai Zasshi 2015; 112: 880–887.
27. Xie H, Lv J, Ji Y, et al. Primary hepatic mucosa-associated lymphoid tissue lymphoma: a case report and literature review. Medicine (Baltimore) 2019; 98: e15034.
28. Yang XW, Tan WF, Yu WL, et al. Diagnosis and surgical treatment of primary hepatic lymphoma. World J Gastroenterol 2010; 16: 6016–6019.
29. Yasuda T, Nakagawa S, Imai K, et al. A case of primary hepatic mucosa-associated lymphoid tissue lymphoma incidentally found in the sustained virological response state of chronic hepatitis C: review of the literature of this rare disease. Int Cancer Conf J 2020; 9: 59–65.
30. Betianu CI, Dima A and Pavaloiu G. Primary hepatic mucosa-associated lymphoid tissue lymphoma in a patient with no chronic liver disease: Case report. Radiol Case Rep 2017; 12: 715–719.
31. Haeffliger S, Milowich D, Sciarra A, et al. Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence? *Ann Hematol* 2019; 98: 1513–1516.
32. Bao C, Wei J, Zhao X, et al. Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in primary hepatic mucosa-associated lymphoid tissue lymphoma: a case report and review of the literature. *Medicine (Baltimore)* 2018; 97: e9877.
33. Panda SS, Baisakh M, Panda A, et al. Primary hepatic marginal zone lymphoma: a rare coincidence. *Curr Probl Cancer* 2018; 42: 322–328.
34. Osawa T, Komaya K, Arikawa T, et al. A case of primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma. *J Hepatobiliary Pancreat Sci* 2017; 24 Suppl 1: 293.
35. Kawaoka T, Aikata H, Inagaki Y, et al. Enhanced ultrasonography detection of mucosa-associated lymphoid tissue of the liver with penetrating vessels in a tumor-case report. *Acta Hepatol Jpn* 2017; 58: 280–288.
36. Fujiwara Y, Sakamoto K, Tokuhisa Y, et al. Two cases of primary hepatic mucosa-associated lymphoid tissue(MALT) lymphoma. *Gan To Kagaku Ryoho* 2016; 43: 1794–1796.
37. Huti E, Gunel N and Berdica L. Primary hepatic low-grade B-cell lymphoma: a case report. *Eur J Cancer Suppl* 2010; 8: 13–14.
38. Prabhu RM, Medeiros LJ, Kumar D, et al. Primary hepatic low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) associated with primary biliary cirrhosis. *Mod Pathol* 1998; 11: 404–410.
39. Luppi M, Grazia Ferrari M, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. *Leukemia* 1996; 10: 351–355.
40. Doi H, Horiike N, Hiraoka A, et al. Primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type: case report and review of the literature. *Int J Hematol* 2008; 88: 418–423.
41. Luppi M, Longo G, Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. *Br J Haematol* 1996; 94: 373–375.
42. Pioltelli P, Zehender G, Monti G, et al. HCV and non-Hodgkin lymphoma. *Lancet* 1996; 347: 624–625.
43. Takeshima F, Kunisaki M, Aritomi T, et al. Hepatic mucosa-associated lymphoid tissue lymphoma and hepatocellular carcinoma in a patient with hepatitis B virus infection. *J Clin Gastroenterol* 2004; 38: 823–826.
44. Nart D, Ertan Y, Yilmaz F, et al. Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a liver transplant patient with hepatitis B cirrhosis. *Transplant Proc* 2005; 37: 4408–4412.
45. Iida T, Iwahashi M, Nakamura M, et al. Primary hepatic low-grade B-cell lymphoma of MALT-type associated with Helicobacter pylori infection. *Hepatogastroenterology* 2007; 54: 1898–1901.
46. Avlonitis VS and Linos D. Primary hepatic lymphoma: a review. *Eur J Surg* 1999; 165: 725–729.
47. Liang Y, Yang Z and Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. *Hepatology* 2012; 56: 1409–1417.
48. Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. *Ultraschall Med* 2008; 29: 28–44.
49. Shiozawa K, Watanabe M, Ikehara T, et al. A case of contiguous primary hepatic marginal zone B-cell lymphoma and hemangioma ultimately diagnosed using contrast-enhanced ultrasonography. *Case Rep Oncol* 2015; 8: 50–56.
50. Albano D, Borghesi A, Bosio G, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma: 18F-FDG PET/CT and CT findings in 28 patients. *Br J Radiol* 2017; 90: 20170311.
51. Albano D, Bosio G, Orlando E, et al. Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated
lymphoid tissue lymphoma: A case series. *Hematol Oncol* 2017; 35: 884–889.

52. Albano D, Durmo R, Treglia G, et al. 18F-FDG PET/CT or PET role in MALT lymphoma: an open issue not yet solved—A critical review. *Clin Lymphoma Myeloma Leuk* 2020; 20: 137–146.

53. Albano D, Bertoli M, Ferro P, et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. *Eur J Nucl Med Mol Imaging* 2017; 44: 589–597.

54. Albano D, Giubbini R and Bertagna F. 18F-FDG PET/CT and primary hepatic MALT: a case series. *Abdom Radiol (NY)* 2016; 41: 1956–1959.

55. Hamada T, Kakizaki S, Koiso H, et al. Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma. *Clin J Gastroenterol* 2013; 6: 150–155.

56. Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. *Eur J Haematol* 2007; 79: 205–209.

57. Yu YD, Kim DS, Byun GY, et al. Primary hepatic marginal zone B cell lymphoma: a case report and review of the literature. *Indian J Surg* 2013; 75: 331–336.

58. Albano D, Bosio G, Giubbini R, et al. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. *Leuk Lymphoma* 2017; 58: 2328–2334.

59. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readressed: a study of 766 patients. *J Nucl Med* 2010; 51: 25–30.

60. Park YK, Choi JE, Jung WY, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma as an unusual cause of malignant hilar biliary stricture: a case report with literature review. *World J Surg Oncol* 2016; 14: 167.

61. Baumhoer D, Tzankov A, Dirnhofer S, et al. Patterns of liver infiltration in lymphoproliferative disease. *Histopathology* 2008; 53: 81–90.

62. Gockel HR, Heidemann J, Lugering A, et al. Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma. *Eur J Haematol* 2005; 74: 445–447.

63. Chen F, Ike O, Wada H, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma 8 years after resection of the same type of lymphoma of the liver. *Jpn J Thorac Cardiovasc Surg* 2000; 48: 233–235.

64. Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. *Semin Hematol* 1999; 36: 139–147.